Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

- PMLiVE

Lilly pays $29m to settle foreign bribery charges

US Securities and Exchange Commission charges centre on activities in Russia, China, Brazil and Poland

- PMLiVE

Lilly stops tabalumab trial in arthritis on efficacy grounds

Will take a charge of around $20m to $35m

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Postcards from China, part 3

Improving market access through integrated solutions

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

- PMLiVE

Lilly takes Xeljanz rival baricitinib into phase III

Its partner Incyte says baricitinib could become the number one JAK inhibitor for RA

- PMLiVE

BMS’ Orencia matches Humira in trial

Head-to-head study shows subcutaneous version as effective as Abbott's drug

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

Charles River Laboratories acquires Chinese research company

Pays $27m for Beijing-based Vital River

Market access opportunities in China

Pope Woodhead highlights the key steps to accessing the high-value therapeutics market in China

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links